

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 12, 2009

Ohr Pharmaceutical, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of
Incorporation)

333-88480

(Commission File Number)

#04-3648721

(IRS Employer Identification No.)

489 5th Ave, 28th Floor, New York, NY

(Address of Principal Executive Offices)

10017

(Zip Code)

Registrant's telephone number, including area code: (212)-682-8452

1245 Brickyard Rd. Suite 590, Salt Lake City, Utah 84106

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On April 8, 2009, the Registrant entered into an Employment Agreement with Dr. Irach Taraporewala who will serve as Chief Executive Officer and Mr. Sam Backenroth who will serve as Vice President of Business Development and Interim Chief Financial Officer. In connection with the employment agreements the Registrant received a letter of Resignation from Mr. Andrew Limpert who is resigning from his positions as Interim Chief Executive Officer, Chief Financial Officer and Board Director. A copy of the press release regarding the management change is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No. Description

10.16 Employment Agreement with Dr. Irach Taraporewala
10.17 Employment Agreement with Mr. Sam Backenroth
99.1 Press Release Dated April 12, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OHR PHARMACEUTICAL, INC.

Dated: April 12, 2010

By: /s/ Irach Taraporewala

Dr. Irach Taraporewala, President and CEO

Ohr Pharmaceutical, Inc
1245 Brickyard Road, #590
Salt lake City, Utah 84106
801-433-2000 ph
801-433-2222 fx

February 25, 2010

Dr. Irach Taraporewala
9009 N Fm 620
Austin, TX 78726

Dear Irach:

On behalf of Ohr Pharmaceutical Inc., I am pleased to offer you employment as Chief Executive Officer for Ohr, reporting to the Board of Directors. Your base salary will be at a bi-weekly rate of \$5000.00 which is annualized at a rate of \$130,000. Your start date will be Monday, April 12, 2010

You will be granted incentive stock options to purchase 800,000 shares of Ohr common stock at \$0.50, 400,000 options will vest immediately upon your employment and the rest will vest on an annual basis of 100,000 options per installment while employed at Ohr.

Your employment will renew automatically on an annual basis. This is the full and complete agreement between us on this term. This provision can only be modified in writing signed by both you and an officer of the Company.

Your employment pursuant to this offer is contingent on you signing a Proprietary Information and Inventions Agreement, covering the ownership of any intellectual property developed by you and confidentiality obligations.

We very much hope that you will accept our offer and look forward to having you on the team.

Sincerely yours,

Andrew Limpert
Interim CEO

I accept the offer of employment above.

Name

Date

Ohr Pharmaceutical, Inc
1245 Brickyard Road, #590
Salt lake City, Utah 84106
801-433-2000 ph
801-433-2222 fx

February 26, 2010

Sam Backenroth
1620 Avenue I
Apartment 310
Brooklyn, NY 11230

Dear Sam:

On behalf of Ohr Pharmaceutical Inc., I am pleased to offer you employment as VP of Business Development and Interim Chief Financial Officer for Ohr, reporting to the Board of Directors. Your base salary will be at a bi-weekly rate of \$2,384.61 which is annualized at a rate of \$62,000. Your start date will be Monday, April 12, 2010.

You will be granted incentive stock options to purchase 200,000 shares of Ohr common stock at \$0.50, 120,000 options will vest immediately upon your employment and the rest will vest on an annual basis of 20,000 options per installment while employed at Ohr. You will also receive a bonus of 50,000 shares for each year of your employment. In the event that Ohr closes a multimillion dollar financing, at your option, your bonus can be substituted with \$20,000 in cash.

Your employment will renew automatically on an annual basis, and your compensation arrangement will be subject to an annual review (on or prior to the anniversary of this letter) by the Board of Directors, under terms and conditions mutually acceptable to both parties. This is the full and complete agreement between us on this term. This provision can only be modified in writing signed by both you and an officer of the Company.

Your employment pursuant to this offer is contingent on you signing a Proprietary Information and Inventions Agreement, covering the ownership of any intellectual property developed by you and confidentiality obligations.

We very much hope that you will accept our offer and look forward to having you on the team.

Sincerely yours,

Andrew Limpert
Interim CEO

I accept the offer of employment above.

Name

Date

OHR PHARMACEUTICAL INC

NEWS RELEASE for April 12, 2010

Contact: Allen & Caron Inc
Jill Bertotti (investors)
jill@allencaron.com
Len Hall (media)
len@allencaron.com
949/474-4300

OHR PHARMACEUTICAL BOLSTERS SENIOR MANAGEMENT TEAM

CEO Dr. Irach Taraporewala Brings Lengthy Experience in Drug Development, Regulatory Strategy; Sam Backenroth Named Interim CFO, VP Business Development

NEW YORK, NY (April 12, 2010)...Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that Dr. Irach B. Taraporewala, B.S., M.S., Ph.D., a veteran healthcare executive with lengthy experience in drug development and regulatory strategy, was named Chief Executive Officer, effective immediately. Dr. Taraporewala replaces Andrew Limpert, the Company's former Interim Chief Executive Officer and Chief Financial Officer, who resigned to pursue other business opportunities. The Company also named Sam Backenroth interim Chief Financial Officer and Vice President of Business Development. Mr. Backenroth has executive experience in financing biotechnology companies and he most recently worked at The Benchmark Company LLC, an investment bank specializing in micro-cap biotechnology transactions.

Dr. Taraporewala, 53, was formerly Vice President of Regulatory Affairs and Clinical Research at Austin, TX-based Mystic Pharmaceuticals Inc. where he led the regulatory strategy for the company's ophthalmic and intranasal drug products and drug delivery systems. Prior to that, Dr. Taraporewala served as Senior Consultant in the Drug Development Consulting division of Boston-based PAREXEL International Corp. (NASDAQ:PRXL), a leading global pharmaceutical services provider, where he provided technical expertise and regulatory advice to small and large biotechnology and pharmaceutical company clients worldwide, and also conducted due diligence for companies and venture capital firms on technology and portfolio evaluation and product acquisitions.

He has also served as principal investigator on four National Institute of Health and U.S. Department of Defense-funded biomedical research grants on antiviral drugs, DNA-based cancer diagnostics and on antimalarial compound development.

"Dr. Taraporewala and Sam Backenroth have the perfect kinds of experience and business acumen we need to bring our rich portfolio of compounds to the global marketplace," said Ira Greenstein, Chairman of the Board of Directors. "Dr. Taraporewala helped take our immunomodulator drug, OHR/AVR118, into clinical trials so he knows first-hand the significant potential it holds for late-stage cancer patients and literally millions of others with serious debilitating diseases. Sam has experience in strategic business development in biotech as well as mergers and acquisitions. We welcome both men at this very important and exciting time for Ohr Pharmaceutical and we look forward to the leadership and strategic advancement they will bring to us."

"I would also like to thank Andrew Limpert," continued Mr. Greenstein, "on behalf of all shareholders, for stepping in as Interim CEO and for being instrumental in helping us guide the Company's strategy during its formative stage."

From 1998 to 2004, Dr. Taraporewala was Director of Chemistry and Quality Control at Yonkers, NY-based Advanced Viral Research Corporation where he helped take OHR/AVR118, an immunomodulator drug, into clinical trials for AIDS, cancer cachexia and rheumatoid arthritis. At Advanced Viral Research he worked closely with Shalom Hirschman, M.D., Ohr's Chief Science Advisor. Prior to that, Dr. Taraporewala worked in research and development at Ciba-Geigy, which later merged with Sandoz to become Novartis.

Dr. Taraporewala earned bachelors' and masters' degrees in chemistry and microbiology from the University of Bombay, India and a Ph.D. in medicinal chemistry from the Philadelphia College of Pharmacy. He conducted postdoctoral research at the University of Texas at Austin, the University of Minnesota and the Southwest Foundation for Biomedical Research. Dr. Taraporewala has multiple scientific publications and patents to his credit, and has lectured extensively.

Mr. Backenroth, 26, graduated from Touro College with a bachelor's degree in finance.

About Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc. (www.ohrpharmaceutical.com) (OTCBB:OHRP) is a pharmaceutical company dedicated to the development of first in class drugs for underserved therapeutic needs. Currently, Ohr is focused on the development of two drugs from its pipeline of candidate therapeutics, OHR/AVR118 for the treatment of Cachexia and EVIZON™ for the treatment of wet-AMD.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.